Table 7.

Long-term outcome of non-Stx–HUS patients

	No mutation, no.	CFH mutation, no.	MCP mutation, no.	IF mutation, no.	P1	P2	P3
Patients with remission	36 (84)	9 (40)	12 (14)	2 (6)	.03	.007	<.001
Patients with complete remission	22 (36)	3 (9)	4 (12)	2 (2)	.13	.09	>.999
Patients with complete remission, after recurrences	14 (36)	6 (9)	8 (12)	0 (2)	.13	.09	>.999
Patients with no remission	48 (84)	31 (40)	2 (14)	4 (6)	.03	.003	<.001
Chronic renal insufficiency	5 (48)	3 (31)	0 (2)	0 (4)	.91	.63	.64
ESRF	32 (48)	13 (31)	2 (2)	4 (4)	.03	.32	.29
Death	11 (48)	15 (31)	0 (2)	0 (4)	.019	.44	.18

IF mutation group has not been included in statistical analysis. The numbers of patients for whom data were available are reported in parentheses.

P1 indicates no mutation versus CFH mutation; P2, no mutation versus MCP mutation; and P3, CFH mutation versus MCP mutation.